Trifluoperazine

Limits on what this shows

• Key null/negative findings: In cultured rat forebrain neurons, trifluoperazine (with dibucaine) instead inhibited glutamate-induced mitochondrial depolarization, i.e. it was protective against an excitotoxic mitochondrial insult in that model, the opposite direction from the isolated-mitochondria inhibition findings. Effective concentrations in the isolated-mitochondria work are in the micromolar-to-millimolar range, well above typical clinical plasma concentrations (nanomolar range), limiting translation to patients at therapeutic doses.
• At-risk subgroups: None identified in human data; no subgroup analysis exists because no human population study exists.

Regulatory status

Not addressed in the FDA label or any label reviewed.

Population evidence

None (no human population study). All supporting evidence is in vitro or ex vivo, using trifluoperazine itself.

Mechanism

Trifluoperazine inhibited electron transport and ATPase activity in isolated plant mitochondria, and inhibited mitochondrial respiration in isolated rat skeletal-muscle mitochondria; mechanism proposed via calmodulin antagonism and direct membrane/enzyme effects rather than a nutrient-cofactor deficiency.

Counter-evidence held on record

Direction is model-dependent: isolated mitochondria and cell-free ATPase preparations show inhibition, while one intact-neuron model shows protection against a different mitochondrial insult. This is mechanistic plausibility only, not a demonstrated clinical energy deficit. This is pharmacologic enzyme inhibition demonstrated in vitro, not evidence of a nutrient or cofactor deficiency, and must not be used to justify CoQ10 or other supplementation (see Fails verification, Coenzyme Q10).

Limits on what this shows

• Key null/negative findings: A separate, class-level (not trifluoperazine-confirmed) literature associates chronic typical-antipsychotic treatment with elevated oxidative-stress markers in patients who develop tardive dyskinesia; this runs in the opposite direction from the trifluoperazine-specific protective findings above and is noted as a competing explanation rather than resolved evidence, since the drugs studied in that literature were not confirmed to include trifluoperazine itself.
• At-risk subgroups: None defined in human data.

Regulatory status

Not addressed in the FDA label.

Population evidence

None (all in vitro/animal, using trifluoperazine itself).

Mechanism

Trifluoperazine protected brain plasma-membrane Ca2+-ATPase from oxidative damage in an ex vivo model; mitigated cyclophosphamide-induced hepatic oxidative stress, inflammation, and apoptosis in mice via modulation of AKT/mTOR-driven autophagy and the Nrf2/HO-1 antioxidant signaling pathway; protected PC12 cells from hydrogen-peroxide-induced apoptosis; and reduced cuprizone-induced demyelination in mice via Nrf2 and IKB pathway effects. Four independent trifluoperazine-specific studies, across different injury models, converge on an antioxidant/cytoprotective rather than pro-oxidant direction.

Counter-evidence held on record

The tardive-dyskinesia oxidative-stress literature is a real, published competing signal, but it is class-level and does not name trifluoperazine in the studied drugs, so it cannot be credited as drug-specific counter-evidence here; it is disclosed for completeness. This is an excess/protective-direction finding, not a deficiency. It must never be read as license to reduce dietary antioxidant intake, and it does not establish that trifluoperazine lowers oxidative-stress risk in treated patients generally.

Limits on what this shows

• Key null/negative findings: Deferoxamine and ferrostatin-1 each independently rescued cells from trifluoperazine-induced death in the Tsai study, confirming the iron-dependence of the mechanism rather than a generic cytotoxic effect. Separately, a non-drug-specific literature on serum iron in catatonia/neuroleptic malignant syndrome (Lee et al. 1998, Biological Psychiatry, PMID 9777183) was re-checked this review via its ScienceDirect abstract (direct PubMed fetch was again blocked by a reCAPTCHA interstitial); the abstract still names only "neuroleptics" generically ("Neuroleptics were used in 5 of them, and all 5 evolved into NMS"), so trifluoperazine's inclusion in that cohort remains unconfirmed, and that finding is disclosed but not used as support here; its direction (low baseline iron as a risk marker for a drug complication) is in any case unrelated to the ferroptosis mechanism above.
• At-risk subgroups: None in human or psychiatric populations; both ferroptosis studies are preclinical oncology/drug-repurposing work at concentrations (low-to-high micromolar) well above typical trifluoperazine steady-state psychiatric plasma levels (nanomolar range).

Regulatory status

Not addressed in the FDA label.

Population evidence

None human/psychiatric. Tsai et al. 2024, "Repurposing of the Antipsychotic Trifluoperazine Induces SLC7A11/GPX4-Mediated Ferroptosis of Oral Cancer via the ROS/Autophagy Pathway," International Journal of Biological Sciences (PMID 39664583, DOI 10.7150/ijbs.99859, open access via PMC11628333, fully read for this entry): oral squamous cell carcinoma lines Ca9-22 and HSC-3, trifluoperazine itself tested at 3, 10, and 30 micromolar (IC50 approximately 23 to 27 micromolar at 24 hours); trifluoperazine significantly increased reactive oxygen species and lipid peroxidation and triggered ferroptotic death, rescued by the iron chelator deferoxamine and by the ferroptosis inhibitor ferrostatin-1; it upregulated the pro-ferroptotic proteins FTH1 (ferritin heavy chain) and NCOA4 (the ferritinophagy receptor) while downregulating SLC7A11 and GPX4, and reduced tumor growth in a zebrafish xenograft at 0.3 to 3 micrograms/mL. A second study, Xu et al. 2026, "Trifluoperazine induces ferroptosis in acute myeloid leukemia by suppressing the Nrf2/SLC7A11/GPX4 axis," European Journal of Pharmacology (PMID 42178012), was identified only via a PubMed search-results listing (title, journal, year, and a brief description of ferrostatin-1 rescue and synergy with the ferroptosis-inducer erastin); direct fetch of its PubMed and Europe PMC records was rate-limited (429) on repeated attempts during this review, so it is disclosed as corroborating context found via a search listing only, not as independently opened and read, and is not the primary basis for this grade.

Mechanism

Iron-dependent lipid peroxidation (ferroptosis): trifluoperazine shifts ferritin handling toward ferritinophagy-linked iron release (FTH1/NCOA4 up) while suppressing the cystine/glutathione/GPX4 antioxidant defense that normally limits iron-catalyzed lipid-radical chain reactions.

Counter-evidence held on record

This is a drug-specific mechanism finding about iron-dependent cell death in cancer cell lines under oncology-repurposing investigation, not a measured change in iron status, hemoglobin, or anemia risk in psychiatric patients taking trifluoperazine at standard doses. Must not be read as a deficiency claim, and must not be used to justify iron supplementation or restriction in patients taking this drug for its approved psychiatric indication. This ferritin/ferritinophagy mechanism is distinct from, and should not be confused with, the catatonia/NMS serum-iron literature, whose cohort still cannot be confirmed to include trifluoperazine (see Overlap map, no shared source).

Limits on what this shows

• Key null/negative findings: No modern replication of the 1974 ceruloplasmin-binding assay, with any phenothiazine, was located. No study measuring serum copper, ceruloplasmin, or copper absorption in trifluoperazine-treated patients was found despite repeated PubMed search-listing queries this review ("trifluoperazine ceruloplasmin"; "trifluoperazine serum copper schizophrenia trace element"), both of which PubMed auto-corrected or silently dropped the word "trifluoperazine" from, returning only generic ceruloplasmin biochemistry or disease-level (not drug-specific) schizophrenia trace-element literature; this confirms no indexed trifluoperazine-copper record exists, rather than reflecting a search-phrasing failure.
• At-risk subgroups: Not established for trifluoperazine.
• Counter-evidence on record: The two previously identified tangential studies remain excluded from grading: a depot-neuroleptic serum-copper-elevation study with agents unnamed is not credited because trifluoperazine is not typically formulated as a depot preparation (unlike fluphenazine decanoate, which this project's fluphenazine dossier extrapolates to on that basis) and so is not a plausible cohort member; an atypical-antipsychotic-only trace-element study tested only chemically distinct atypical agents and fails the cohort test entirely, even as Tier C.

Regulatory status

Not addressed in the FDA label.

Population evidence

None for trifluoperazine itself. Løvstad, "Interaction of phenothiazine derivatives with human ceruloplasmin," Biochemical Pharmacology 1974;23(6):1045-52 (PMID 4151049, confirmed by direct PubMed fetch during this review): tested chlorpromazine, promazine, triflupromazine, and methotrimeprazine (levomepromazine) against human ceruloplasmin, examining protein binding and oxidation-reduction interactions involving dopamine, ascorbic acid, glutathione, iron, NAD, and NADP. Trifluoperazine itself was not among the four compounds tested. This same source underlies the Copper (and, via its ferroxidase logic, the Iron) entries in this project's chlorpromazine dossier; see Overlap map for the cross-dossier disclosure.

Mechanism

Proposed as a property of the oxidizable phenothiazine tricyclic ring system, shared by all four tested compounds and by trifluoperazine, rather than of any particular N10 side chain; however, this is inferred, not demonstrated. All four tested compounds carry an aliphatic or related side chain, while trifluoperazine carries a piperazine side chain, a structurally distinct phenothiazine subclass with a different potency, receptor-binding, and anticholinergic/antihistaminic profile. Whether the side-chain difference changes the ceruloplasmin interaction has not been tested for any piperazine phenothiazine.

Counter-evidence held on record

If a real effect exists for trifluoperazine, the direction suggested by this class-level chemistry is altered handling or possible interaction, not a copper deficiency. Must never be read as support for copper supplementation; extrapyramidal or neurologic symptoms on trifluoperazine should be worked up as the drug's own labeled dopaminergic pharmacology first, not as a copper disorder. Trifluoperazine itself was not tested in the cited source; this is a labeled class extrapolation across a side-chain subclass boundary (piperazine vs. aliphatic phenothiazines) and should be weighted accordingly.

Limits on what this shows

• Key null/negative findings: No study measuring actual gut microbiome composition (sequencing-based) in trifluoperazine-treated patients was located. The active MICs (tens to hundreds of micrograms/mL) are far above reported trifluoperazine plasma concentrations at standard oral doses (typically low nanograms/mL), so systemic exposure is unlikely to reach these levels; gut luminal concentration after oral dosing was not measured in any source reviewed and remains unknown.
• At-risk subgroups: None defined; no in vivo human data exists.

Regulatory status

Not addressed in the FDA label; not an approved antimicrobial indication.

Population evidence

None. In vitro MIC testing only, using trifluoperazine itself (minimum inhibitory concentration 32 to 128 micrograms/mL against S. aureus including clinical MRSA isolates, and 64 to 256 micrograms/mL against E. coli and Acinetobacter baumannii). A separate older review also cites trifluoperazine curing Salmonella typhimurium infection in mice in vivo.

Mechanism

Direct antibacterial activity, structurally shared with the phenothiazine/thioxanthene chemical scaffold; of 20 antipsychotic compounds tested across chemical classes in one study, only phenothiazines and thioxanthenes (not butyrophenones, benzamides, or atypical antipsychotics) showed activity, which supports a class-coherent, mechanism-plausible effect rather than an isolated artifact.

Counter-evidence held on record

The large gap between in vitro active concentrations and achievable plasma levels is the main limitation; this is flagged explicitly rather than smoothed over. This is mechanistic plausibility from in vitro antibacterial testing, not a demonstrated clinical effect on the gut microbiome, and is not a basis for probiotic or other supplementation advice.

Limits on what this shows

• Key null/negative findings: No human bioenergetic (for example, phosphorus-31 MRS or muscle biopsy ATP) study in trifluoperazine-treated patients was located to confirm or refute translation to living tissue at clinical doses.
• At-risk subgroups: None identified; no human data exists to stratify.

Regulatory status

Not addressed in the FDA label.

Population evidence

None. In vitro only, using trifluoperazine itself on particulate and soluble mitochondrial F1-ATPase preparations.

Mechanism

Trifluoperazine inhibited both ATP synthesis and ATP hydrolysis by mitochondrial F1, competing with inorganic phosphate at the catalytic site; consistent with the electron-transport and respiration inhibition described under Mitochondrial burden, sharing the same underlying primary literature (see Overlap map).

Counter-evidence held on record

Effective concentrations in the cited enzyme work are far above steady-state plasma levels seen at standard oral dosing, so a clinically meaningful ATP deficit in patients has not been shown. This describes direct enzyme inhibition in vitro, not a measured ATP or CoQ10 deficiency in patients, and does not support a supplementation recommendation.

Limits on what this shows

• Why no grade: The dual condition is met once the label's hematologic-toxicity language is correctly excluded as the drug's own adverse-effect profile rather than a nutrient finding: no Tier B/C evidence ties trifluoperazine to a nutrient-mediated impairment of oxygen delivery or utilization (for example, via iron-limited erythropoiesis, altered 2,3-BPG, or hemoglobin synthesis), and no circulating consumer claim of this specific kind was found to rebut as white.

Mechanism clarification (not graded)

Agranulocytosis, thrombocytopenia, anemia, and pancytopenia are listed on the trifluoperazine label as adverse reactions requiring monitoring (sore throat, signs of infection). These are idiosyncratic or dose-related drug toxicities, analogous to how a beta-blocker's intended reduction in heart rate is not an oxygen-delivery nutrient deficiency; "anemia" here is an outcome label, not a measured iron, B12, or folate deficit, and is not regraded as one.

Channels tried

DailyMed/FDA label fetch (succeeded, supplied the hematologic warning language above); WebSearch for trifluoperazine-specific erythropoiesis, hemoglobin synthesis, or oxygen-carrying-capacity mechanisms (no drug-specific results beyond the generic blood-dyscrasia warning); PubMed direct fetch generally blocked (CAPTCHA) during the original review. On this repair pass, PubMed search-listing queries combining trifluoperazine with anemia, hemolysis, methemoglobin, and erythrocyte terms were re-run directly: none of the ten results returned on the first page were drug-specific (sickle cell disease, neonatal erythrocytes, hemoglobin variants, and unrelated topics, with no mention of trifluoperazine). A further search combining trifluoperazine with erythrocyte-deformability/calmodulin terms surfaced one possible lead, Murakami 1987 ("Changes of erythrocyte deformability induced by calcium accumulation and calmodulin inhibitors," Nihon Seirigaku Zasshi, PMID 3625566), but whether trifluoperazine specifically was among the "calmodulin inhibitors" tested could not be confirmed: direct fetch of this record was rate-limited (429) on both PubMed and the Europe PMC REST API on repeated attempts, so it is disclosed as an unconfirmed, inaccessible lead and is not cited as evidence. Europe PMC and PubMed single-record pages continued to be intermittently rate-limited or CAPTCHA-blocked throughout this repair pass. No genuine drug-specific nutrient-mediated oxygen-delivery literature was found through any channel tried, across two review passes.